Amberstone Biosciences snags $12m Series A

Amberstone Biosciences, an emerging biotherapeutics company, has closed $12 million in Series A financing.

To view this content, you need to sign in.

You should only be asked to sign in once. Not the case? Click here

Register now to access this content and more for free.

Share this